Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).Â
Featured Article
Xometry CEO Sanjeev Singh Sahni on how AI and digital networks are reshaping manufacturing supply chains
Australian manufacturers have long competed against distance. In an exclusive interview with Australian Manufacturing, Xometry CEO Sanjeev Singh Sahni discusses how AI can help manufacturers access more production capacity and simplify traditionally email-driven supply chains.
